Enveric Biosciences Inc. has announced positive preclinical results for its lead drug candidate, EB-003, aimed at treating severe chronic depression and despair. Conducted in the Open Space Forced Swim Test, a recognized animal model for psychiatric behavior, the study demonstrated significant improvements in depression-like behavior in mice. An oral dose of 30 mg/kg of EB-003 was shown to reduce depression-like symptoms within 30 minutes, with results comparable to the effects of the antidepressant Imipramine. Additionally, extended daily administration of EB-003 over 22 days revealed no adverse effects, indicating the compound's safety for long-term use. These findings support Enveric's plans to proceed with an Investigational New Drug application.